Application of Probiotics in Autoimmune Diseases
The gut microbiota may cause or contribute to the establishment of infectious diseases and trigger autoimmune disorders. The role of probiotics in regulating the gut microbiota offers potential for the use of probiotics in the treatment of autoimmune diseases. Creative Enzymes offers a wide range of probiotic strains that can be used to effectively improve or treat immune-mediated diseases. In addition, our advanced research platform can help researchers elucidate the role of the microbiota in the development of autoimmune diseases and find new therapeutic approaches.
Gut Microbiota and Autoimmune Diseases
The results of animal researches have suggested the direct involvement of gut microbiota in disease development, and some gut microbiotas are associated with autoimmune diseases. The intestinal dysbiosis observed in autoimmune diseases is associated with reduced bacterial function and diversity, impaired intestinal barrier function, increased inflammation, and decreased intestinal Treg cells. Additionally, the hypotheses proposed to link intestinal dysbiosis with autoimmune diseases include molecular mimicry, bystander T-cell activation, and the amplification of autoimmunity by pro-inflammatory milieu, which is elicited by altered gut microbiota.
Fig. 1 A schematic representation of the intestinal dysbiosis in organ-specific autoimmune diseases in humans. (Leite, 2017)
Probiotics for Autoimmune Diseases
Probiotics influence the systemic immune response and regulate the homeostasis of the microbiota in the gut, and therefore can be used as an adjunctive therapy in the treatment of immune-mediated diseases. The mechanisms proposed to achieve this goal include mucus secretion, antimicrobial peptide production, maintaining the function of the gastrointestinal epithelial barrier, ensuring adequate interaction between the intestinal microbiota and mucosal immune cells, and finally, helping to activate the host immune system in response to pathology. Creative Enzymes provide stable, high-quality probiotics that provide the ideal strain for the treatment of different autoimmune diseases.
- Type 1 Diabetes (T1D)
T1D is characterized by immune destruction of insulin-secreting pancreatic beta cells, leading to exogenous insulin dependence to control blood glucose levels.
Lactobacillaceae: Mice can be protected from T1D by inhibiting IL-1β expression and immunomodulatory indoleamine 2,3-dioxygenase release in non-obese diabetic mice (NOD) and by promoting the differentiation of CD103-tolerant dendritic cells in the gut.
- Multiple Sclerosis (MS)
MS is a chronic inflammatory disease that affects the central nervous system (CNS) and is characterized by an autoimmune response against myelin proteins.
Lactobacillus spp., Bifidobacterium bifidum, Bifidobacterium animalis and Bacteroides fragilis: These species ameliorate CNS inflammation by promoting IL-10 secretion and transforming growth factor-β in EAE mice, inducing a decrease in Th1/Th17 inflammatory subpopulations, and inducing CNS inflammation by inducing Treg cells in the gut mucosa.
Probiotic supplementation containing Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus fermentum and Bifidobacterium bifidum: Improving insulin resistance and reduces inflammatory markers in patients.
- Rheumatoid Arthritis (RA)
RD is characterized by chronic inflammation of multiple joints, bone erosion and cartilage destruction. In addition, it affects internal organs such as the lungs, heart and kidneys.
Bacillus coagulans: Oral administration of Bacillus coagulans with anti-inflammatory effects promotes a decrease in amyloid-like protein levels and a decrease in serum levels of tumor necrosis factor in a rat model of RA.
Lactobacillus casei: After oral treatment, patients had increased serum IL-10 levels and decreased levels of tumor necrosis factor IL-6 and IL-12.
Lactobacillus acidophilus, Bifidobacterium bifidum: Intake of these probiotics can improve DAS28, reduce serum C-reactive protein levels, and promote lower insulin levels.
- Systemic Lupus Erythematosus (SLE)
SLE is characterized by damage to the skin, kidneys, lungs, joints, heart and brain. A decrease in the relative abundance of Lactobacillus spp. and an increase in Lactobacillaceae members were found in female lupus-prone mice.
In a lupus-like animal model, administration of retinoic acid restored Lactobacillus spp. and improved lupus symptoms.
Our Capabilities
- Providing personalized probiotic formulations for specific health demands to help regulate the immune system.
- We link gut ecological dysregulation to autoimmune disease pathogenesis and use all generated data for collaborative discovery of new probiotics, predictive biomarkers and therapeutics for the adjuvant treatment of autoimmune diseases.
- We can evaluate the function and safety of potential probiotic strains and products for use in autoimmune diseases.
Creative Enzymes is a professional and experienced probiotic supplier and service provider. We provide high-quality scientific support for your probiotic research and development in autoimmune diseases. To get more information, please contact us and we will be happy to serve your research demands.
Reference
- Leite.; et al. Intestinal dysbiosis and probiotic applications in autoimmune diseases. Immunology. 2017, 152(1):1-12.
